Chronicles of cancer: A history of mammography

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cleveland institutions to study CAR-T in Non-Hodgkin lymphoma

University Hospitals Cleveland Medical Center press statement

Publish date:: August 16, 2018

Key clinical point: A phase 1 trial of CAR T therapy is enrolling adult patients with NHL who have not responded to standard therapies.

Major finding: The trial site has the ability to manufacture the cells on site, saving patients time.

Study details: A phase 1 trial to evaluate safety.

Disclosures: The study will be funded by University Hospitals Seidman Cancer Center.

Read the article.

Citation:

University Hospitals Cleveland Medical Center press statement

This Week's Must Reads

Polygenic risk score may predict VTE in adolescents, but not adults, with ALL,

Determining cause of skin lesions in COVID-19 patients remains challenging,

Since COVID-19 onset, admissions for MI are down, mortality rates are up,

Elotuzumab-based therapy may benefit post-transplant response in multiple myeloma,

BALL score predicts benefit from ibrutinib therapy in relapsed/refractory CLL patients,

Must Reads in Aggressive Lymphomas

Study Halted; ‘Hyperprogression’ Seen With Nivolumab for R/R PTCL,

CAR T-Cell Therapy Found Safe, Effective For HIV-Associated Lymphoma,

Bispecific CAR T-cell Therapy Yields Complete Responses in Relapsed/Refractory non-Hodgkin Lymphomas,

5F9 Plus Rituximab Take a Bite Out of Drug-Resistant NHL,

‘Encouraging’ Responses Seen With Durvalumab Plus R-CHOP in DLBCL,